Related Experiment Video
Updated: Jan 23, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Targeting Biology in Non-Hodgkin Lymphoma
Mayur Narkhede1, Maryam Sarraf Yazdy1, Bruce D Cheson1
1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center Podium A, 3800 Reservoir Road Northwest, Washington, DC 20007, USA.
Abstract:
Chemotherapy nonspecifically affects all cells undergoing DNA replication and has severe side effects. Understanding of the biology of non-Hodgkin lymphomas has led to development of drugs that target specific lymphoma cell functions and tumor microenvironment. Targeted agents used in combination with chemotherapy pave the way to a chemotherapy-free world. These drugs target multiple oncogenic pathways and modulate the immune system, with better outcomes. Such combinations should be administered only in clinical trials. Incorporating studies of the biology and genetics of these tumors into therapeutic studies may lead to a chemotherapy-free world with improved outcomes and reduced toxicities.
Insights
Targeted therapies offer a promising future for non-Hodgkin lymphoma treatment, potentially reducing reliance on chemotherapy. Further research in clinical trials is crucial for developing chemotherapy-free treatment strategies with improved outcomes and reduced toxicity.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Traditional chemotherapy for non-Hodgkin lymphomas (NHL) lacks specificity, leading to significant side effects due to its impact on all rapidly dividing cells.
- Advances in understanding NHL biology have identified specific molecular targets within lymphoma cells and their microenvironment.
Purpose of the Study:
- To explore the potential of targeted agents, in combination with chemotherapy, to move towards a chemotherapy-free treatment paradigm for NHL.
- To highlight how targeting specific oncogenic pathways and modulating the immune system can improve patient outcomes and reduce treatment toxicities.
Main Methods:
- Review of current understanding of non-Hodgkin lymphoma biology and genetics.
- Analysis of targeted agents that act on specific lymphoma cell functions and the tumor microenvironment.
- Evaluation of combination strategies involving targeted agents and chemotherapy within clinical trial settings.
Main Results:
- Targeted agents demonstrate the ability to inhibit multiple oncogenic pathways crucial for lymphoma cell survival and proliferation.
- These targeted agents can modulate the tumor microenvironment and the immune system, leading to potentially better therapeutic outcomes.
- Combinations of targeted agents and chemotherapy show promise in improving efficacy and reducing the severe side effects associated with traditional chemotherapy.
Conclusions:
- The development of targeted therapies represents a significant step towards a chemotherapy-free future for non-Hodgkin lymphoma patients.
- Integrating biological and genetic insights into therapeutic strategies is key to achieving improved outcomes and reduced toxicities.
- Further investigation and administration of these novel combinations exclusively within clinical trials are essential for validating their safety and efficacy.
Related Concept Videos
What is Conservation Biology?
Biological Effects of Radiation
Synthetic Biology
Golden rice
Golden rice is a genetically modified...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
Biological Influences on Intelligence
Applications Of NMR In Biology

